Safety and efficacy of lamivudine/dolutegravir vs. bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral-naive adults with HIV-1 infection in Shanghai, China: a single-centre retrospective study
Journal of Medical Microbiology · 2025
DOI: 10.1099/jmm.0.001949 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Medical Microbiology, 2025. Verfasst von Junyang Yang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, PR China. Hauptthemen laut MEDLINE: HIV Infections, Pyridones, Lamivudine, Tenofovir. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Science and Technology Development Foundation, Shanghai Municipal Health Commission.
Abstract (Originalsprache)
Introduction
Lamivudine plus dolutegravir (3TC/DTG) and bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) regimens are commonly used as first-line treatments for people living with human immunodeficiency virus (HIV) (PLWH) worldwide. Gap Statement. There are limited comparative data on the antiviral activity and safety between these regimens in ART-naive PLWH, particularly in China, where the 3TC/DTG regimen was integrated into first-line therapy in 2021 and gained broader adoption after its inclusion in the National Health Insurance in 2022.
Aims
This study aims to provide real-world evidence comparing the 3TC/DTG regimen to the B/F/TAF regimen in ART-naive PLWH in China. Methodology. This retrospective study enrolled PLWH initiating ART with either 3TC/DTG or B/F/TAF in Shanghai from January 2020 to January 2023. Demographic characteristics and clinical information were collected and compared for each patient.
Results
A total of 380 eligible, ART-naive PLWH were included, with 190 patients in the 3TC/DTG group and 190 patients in the B/F/TAF group. Following the initiation of ART, most patients (94.1 and 89.3% for 3TC/DTG and B/F/TAF groups, respectively) achieved viral suppression (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, PR China.
- Department of Nursing, Shanghai Public Health Clinical Center, Fudan University, Shanghai, PR China.
- No. 2 High School of East China Normal University, SongJiang, Shanghai, PR China.
- Department of Community, Shanyang Community Health Service Center, Shanghai, PR China.
Förderung
- Shanghai Science and Technology Development Foundation
- Shanghai Municipal Health Commission
Zitieren
APA
Yang, J., Wang, L., Zhang, X., Liu, L., Shen, Y., Qi, T., Wang, Z., Song, W., Tang, Y., Xu, S., Sun, J., Chen, Y., Shen, Y., Chen, J., & Zhang, R. (2025). Safety and efficacy of lamivudine/dolutegravir vs. bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral-naive adults with HIV-1 infection in Shanghai, China: a single-centre retrospective study. Journal of Medical Microbiology. https://doi.org/10.1099/jmm.0.001949
Vancouver
Yang J, Wang L, Zhang X, Liu L, Shen Y, Qi T, et al. Safety and efficacy of lamivudine/dolutegravir vs. bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral-naive adults with HIV-1 infection in Shanghai, China: a single-centre retrospective study. Journal of Medical Microbiology. 2025. doi:10.1099/jmm.0.001949
BibTeX
@article{Yang2025,
author = {Yang, Junyang and Wang, Lin and Zhang, Xiaoran and Liu, Li and Shen, Yinzhong and Qi, Tangkai and Wang, Zhenyan and Song, Wei and Tang, Yang and Xu, Shuibao and Sun, Jianjun and Chen, Youming and Shen, Yihong and Chen, Jun and Zhang, Renfang},
title = {Safety and efficacy of lamivudine/dolutegravir vs. bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral-naive adults with HIV-1 infection in Shanghai, China: a single-centre retrospective study},
journal = {Journal of Medical Microbiology},
year = {2025},
doi = {10.1099/jmm.0.001949}
}
EUVIMED